Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression
1996

C-myc Expression in Tumor Cells After Cisplatin Treatment

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): TL Walker, JD White, WJ Esdale, MA Burton, EE DeCruz

Primary Institution: Biomedical Research Group, School of Science and Technology, Charles Sturt University

Hypothesis

Antisense therapy directed at c-myc in combination with cisplatin may achieve therapeutic efficacies in vivo that greatly exceed those displayed by either agent in isolation.

Conclusion

Cisplatin treatment leads to a significant increase in c-myc expression in surviving tumor cells, which may contribute to chemoresistance.

Supporting Evidence

  • Surviving tumor cells showed a significant 2-fold increase in c-myc expression at 48 hours and 7 days after cisplatin treatment.
  • Antisense treatment resulted in a 25% growth retardation of tumor cells for up to 4 days.
  • Statistical analysis demonstrated a significant difference in tumor growth rates between treated and untreated groups.

Takeaway

When cancer cells are treated with a drug called cisplatin, they start to make more of a protein called c-myc, which helps them survive. This means they might not die like we want them to.

Methodology

The study used a solid transplantable tumor model in rats, treated with a single dose of cisplatin, and analyzed c-myc expression at different time points.

Limitations

The study primarily focuses on a single animal model and may not fully represent human responses.

Participant Demographics

Syngeneic DA rats, 10-16 weeks old.

Statistical Information

P-Value

0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication